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Introduction
To colonize new areas and establish cell masses suffi  cient for 
further development, both normal progenitor cells and malig-
nant tumor cells must be able to migrate and proliferate. There is 
evidence to suggest that cells may not be able to engage in both 
of these activities simultaneously. In the rat brain, invading 
glioma cells are observed to halt their migration along blood 
vessels during periods of mitosis (Farin et al., 2006), mimicking 
the saltatory pattern of normal glial progenitor migration (Suzuki 
and Goldman, 2003). Correspondingly, the most highly invasive 
glioma cells in human tumors are often found to exhibit the low-
est rates of proliferation and vice versa (Giese et al., 2003). We 
have investigated the role of the NG2 proteoglycan in regulating 
the choice between glioma cell proliferation and motility.
NG2 is expressed by a variety of immature progenitor cell 
types and also by several types of tumors (Stallcup, 2002). Sev-
eral studies suggest a role for NG2 in promoting the proliferation 
and motility that are characteristic of both normal progenitor cells 
and malignant tumor cells (Nishiyama et al., 1996; Burg et al., 
1997; Grako et al., 1999; Ozerdem and Stallcup, 2004). As a 
membrane-spanning molecule, NG2 affects proliferation and 
migration via interactions with both extracellular and intra-
cellular binding partners. The NG2 ectodomain has the ability to 
sequester growth factors and bind to growth factor receptors 
(Nishiyama et al., 1996; Goretzki et al., 1999; Grako et al., 1999), 
infl  uence the processing of kringle domain proteins (Goretzki 
et al., 2000; Chekenya et al., 2002), interact with extracellular 
matrix ligands such as collagen VI (Burg et al., 1996; Tillet et al., 
1997, 2002), and form signaling complexes with α3β1-integrin 
and galectin-3 (Fukushi et al., 2004; Wen et al., 2006). The cytoplas-
mic domain of NG2 is involved in activation of the Rho family 
GTPases Rac and Cdc42 (Eisenmann et al., 1999; Majumdar 
et al., 2003; Yang et al., 2004) as well as in anchorage via the 
PDZ-containing scaffolding proteins MUPP1 and GRIP1 (Barritt 
et al., 2000; Stegmuller et al., 2003).
Although NG2 exhibits some signal-transducing capabili-
ties of its own (Iida et al., 1995; Fang et al., 1999; Tillet et al., 
2002), its ability to enhance signaling by growth factor receptors 
(Nishiyama et al., 1996; Grako et al., 1999) and β1-integrins 
(Iida et al., 1995; Eisenmann et al., 1999; Fukushi et al., 2004; 
Yang et al., 2004) greatly expands the proteoglycan’s scope 
of action. Posttranslational modifi  cations of NG2 provide an 
Differential phosphorylation of NG2 proteoglycan 
by ERK and PKCα helps balance cell proliferation 
and migration
Irwan T. Makagiansar, Scott Williams, Tomas Mustelin, and William B. Stallcup
Cancer Center, The Burnham Institute for Medical Research, La Jolla, CA 92037
T
wo distinct Thr phosphorylation events within the 
cytoplasmic domain of the NG2 proteoglycan help 
regulate the cellular balance between proliferation 
and motility. Protein kinase Cα mediates the phosphoryla-
tion of NG2 at Thr
2256, resulting in enhanced cell motility. 
Extracellular signal–regulated kinase phosphorylates NG2 
at Thr
2314, stimulating cell proliferation. The effects of 
NG2 phosphorylation on proliferation and motility 
are dependent on β1-integrin activation. Differential cell 
surface localization of the two distinctly phosphorylated 
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colocalizes with β1-integrin on microprotrusions from the 
apical cell surface. In contrast, NG2 phosphorylated at 
Thr
2256 colocalizes with β1-integrin on lamellipodia at the 
leading edges of cells. Thus, phosphorylation and the 
  resulting site of NG2–integrin localization may determine 
the speciﬁ  c downstream effects of integrin signaling.
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  important means for regulating its interaction with extracellular 
and cytoplasmic binding partners. We have reported that PKCα-
mediated phosphorylation of Thr
2256 in the NG2 cytoplasmic 
  domain triggers the redistribution of NG2 from apical micro-
processes to lamellipodia on the leading edge of the cell. 
This molecular redistri  bution is accompanied by enhanced 
cell motility (Makagiansar et al., 2004). This has led to our 
current exploration of the extracellular signal–regulated ki-
nase (ERK)–mediated phosphorylation of NG2 at Thr
2314 and the 
contrasting consequences of the two respective phosphorylation 
events on proliferation and motility.
Results
Evaluation of phosphorylation sites 
in the NG2 cytoplasmic domain
The Thr
2256 residue phosphorylated by PKCα is one of several 
Thr residues in the NG2 cytoplasmic domain (Nishiyama et al., 
1991; Makagiansar et al., 2004). Analysis of the cytoplasmic 
domain of rat NG2 for sequences involved in protein–protein 
interaction (Scansite 2.0) identifi  ed the amino acid residues 
2,278–2,290 as a D domain, which is postulated to be a docking 
site for ERK (Fig. 1 A; Fantz et al., 2001). Fig. 1 B shows the 
alignment of the NG2 D-domain sequence with that of other 
proteins with known ERK-docking motifs.
Notably, NG2 also possesses a potential proline-dependent 
phosphorylation site (
2313RTPNP
2317; Fig. 1 A) that conforms to 
the minimal recognition sequence (S/T)P required for phos-
phorylation by ERK (Fantz et al., 2001). The residues surrounding 
Thr
2314 are conserved in the human (Pluschke et al., 1996), 
chimpanzee (GenBank/EMBL/DDBJ accession no. XP_510685), 
mouse (Schneider et al., 2001), and dog (GenBank/EMBL/DDBJ 
accession no. XP_544783) homologues of NG2, which is sug-
gestive of the functional importance of this region.
The NG2 cytoplasmic domain 
is a substrate for ERK-mediated 
phosphorylation
To detect the association between NG2 and ERK, the proteo-
glycan was immunoprecipitated from NG2-transfected U251 
cells (U251/NG2). Immunoblotting for phosphorylated ERK 
(P-ERK) reveals that serum-starved U251/NG2 cells contain 
low levels of P-ERK associated with NG2 (Fig. 1 C). When 
serum-starved cells are treated with 10% serum, increased co-
immunoprecipitation of P-ERK with NG2 is observed. Pretreat-
ment of cells with the MAPK kinase (MEK) 1/2 inhibitor U0126 
largely blocks the P-ERK–NG2 interaction, suggesting that the 
activation of ERK is required for its association with NG2.
To directly test the ability of ERK to phosphorylate 
NG2, we used active recombinant ERK in conjunction with 
γ-[
32P]ATP to carry out in vitro phosphorylation of GST fusion 
proteins containing the cytoplasmic regions of wild-type NG2 
(GST-NG2c) and the Thr point mutants GST-NG2c-T2256E, 
-NG2c-T2265E, -NG2c-T2278E (Makagiansar et al., 2004), and 
-NG2c-T2314E. Results of the phosphorylation reactions were 
analyzed by two-dimensional mapping of tryptic phosphopep-
tides. The phosphopeptide maps of the GST-NG2c-T2265E and 
-NG2c-T2314E fusion proteins differ from those of the other 
species (Fig. 2). GST-NG2c-T2265E lacks the more highly 
charged of two major phosphopeptides derived from the wild-
type fusion protein (spot 1), whereas the more neutral phos-
phopeptide (spot 2) is missing from GST-NG2c-T2314E. 
Simultaneous mutation of both of these Thr sites leads to the 
disappearance of all phosphopeptides from the GST-NG2c-
T2265E/T2314E map, confi  rming the ability of recombinant 
ERK to phosphorylate the NG2 cytoplasmic domain at posi-
tions Thr
2265 and Thr
2314 in vitro.
ERK contributes to the phosphorylation 
of full-length cell surface NG2
In light of artifacts that may occur in vitro, caution must be used 
when interpreting the phosphorylation data in Fig. 2 (Manning 
and Cantley, 2002; Wingate et al., 2006). Therefore, we exam-
ined ERK phosphorylation of full-length NG2 in the context of 
living cells using two different motif-specifi  c antibodies to detect 
Thr phosphorylation. The fi  rst antibody recognizes the sequence 
xTpx(K/R) found at Thr
2265, whereas the second recognizes the 
xTpP motif found at Thr
2314. The specifi  city of these antibodies 
in the context of the NG2 cyto  plasmic domain was confi  rmed 
via immunoblotting of the GST-NG2c fusion protein that had 
Figure 1.  Interaction of NG2 with ERK. 
(A) Scansite analysis of the cytoplasmic sequence 
of rat NG2 identiﬁ  es the amino acids T2278-
L2290 (box) as a putative D domain–docking 
site for ERK. The asterisks denote the putative 
ERK phosphorylation motif x(S/T)P. (B) Align-
ment of T2278-L2290 with known ERK-docking 
sites (D domains) present in Elk-1 (Yang et al., 
1998), death-associated protein kinase (DAPK; 
Chen et al., 2005), MEK1 (Xu et al., 1999), 
JunD (Vinciguerra et al., 2004), and striatal-
  enriched protein tyrosine phosphatase (STEP; 
Paul et al., 2000). Conserved residues are in-
dicated in bold font. Consensus designations: +, 
basic amino acid; φ, hydrophobic amino acid; 
and X, any amino acid. (C) Serum-starved 
U251/NG2 cells were treated with 10% FCS 
for 15 min in the presence or absence of 20 μM 
U0126. Immunoprecipitated samples were ana-
lyzed by Western blotting using antiphospho-
ERK1/2 or anti-NG2 antibodies.CONSEQUENCES OF NG2 PHOSPHORYLATION BY ERK AND PKCα • MAKAGIANSAR ET AL. 157
been phosphorylated in vitro by nonradioactive ERK or PKCα-
catalyzed reactions (unpublished data).
To stimulate the ERK-mediated phosphorylation of full-
length NG2 in living cells, we treated U251/NG2 cells with 
PDGF-BB. This ligand activates both the α and β isoforms of 
the PDGF receptor, triggering the downstream activation of 
  numerous intracellular signaling cascades, including both the 
PKC and MAPK pathways. After PDGF-BB stimulation, total 
cell extracts were examined to confi  rm the activation of PKCα 
and ERK. Levels of P-ERK and PKCα were found to increase 
within 15 to 30 min (Fig. 3 A). In parallel, NG2 was immuno-
precipitated and immunoblotted with the respective phospho-
Thr antibodies, revealing large increases in the quantity of 
phosphorylated NG2 detected by both the anti-xTpP and 
-xTpx(K/R) antibodies (Fig. 3 A). Similar patterns of NG2 
phosphorylation were detected by these same phosphospecifi  c 
antibodies in A375 human melanoma cells (Fig. 3 B). There-
fore, phosphorylation of the proteoglycan is not an artifact of 
its overexpression but a normal physiological consequence of 
PDGF-BB treatment.
It was initially unclear whether NG2 phosphorylation 
detected by the xTpx(K/R) antibody was caused by the ERK-
mediated phosphorylation of Thr
2265 observed in vitro or 
by the reported PKCα-mediated phosphorylation of Thr
2256 
(Makagiansar et al., 2004). To resolve this issue, U251/NG2 cells 
were pretreated either with the MEK1/2 inhibitor U0126 or the 
PKCα inhibitor Gö6976 before the addition of PDGF-BB. U0126 
inhibition of ERK activation did not alter the level of xTpx(K/R) 
phosphorylation (Fig. 3 C). In contrast, this phosphorylation was 
blocked by treatment with Gö6976. These data suggest that the 
PDGF-BB–induced xTpx(K/R) phosphorylation of NG2 is not 
caused by ERK phosphorylation at Thr
2265 but instead by PKCα-
mediated phosphorylation at Thr
2256. Thus, Thr
2265 is unlikely to 
be an ERK phosphorylation site in NG2 expressed in living cells.
The substantial increase in PDGF-BB–induced xTpP mo-
tif phosphorylation implicates Thr
2314 as an in vivo NG2 phos-
phorylation site (Fig. 3 A). This phosphorylation is not observed 
in the presence of U0126 (Fig. 3 C), establishing ERK as the 
likely mediator of Thr
2314 phosphorylation. Interestingly, PDGF-
BB–dependent ERK-mediated Thr
2314 phosphorylation is not 
observed when PKCα activation is blocked by Gö6976 (Fig. 3 C), 
suggesting that PKCα is a key upstream effector of ERK activa-
tion in these cells.
To further establish that Thr
2314 is the sole site of ERK-
 mediated  NG2  phosphorylation in living cells, cells transfected 
with full-length NG2 constructs containing individual T®V 
substitutions (NG2-T2256V, -T2265V, and -T2314V) were stim-
ulated with PDGF-BB in the absence or presence of the U0126 
and Gö6976 inhibitors followed by immunoprecipitation of the 
mutant NG2 proteins. With the exception of the NG2-T2314V 
mutant, phosphorylation was detected in all NG2 species by 
blotting with the anti-xTpP antibody (Fig. 3 D), further estab-
lishing Thr
2314 as the site of ERK phosphorylation. In addition, 
PDGF-BB treatment induced heavy xTpx(R/K) phosphorylation 
of the NG2-T2265 and -T2314 mutants but failed to phosphorylate 
an xTpx(K/R) site in the NG2-T2256V mutant. This identifi  es 
Thr
2256 as the sole PDGF-BB–dependent xTpx(K/R) phosphor-
ylation site in NG2. Thus, by activating both PKCα and ERK 
downstream of PDGF receptors, PDGF-BB stimulation results 
in the phosphorylation of NG2 at both Thr
2256 and Thr
2314.
As a fi  nal demonstration that ERK phosphorylates only 
Thr
2314 in cells, we transfected U251/NG2 cells with a consti-
tutively active MEK mutant (MEK-DD) (Saxena et al., 1999; 
Delmas et al., 2003). As expected, an increase in ERK phos-
phorylation was observed in U251/NG2/MEK-DD cells com-
pared with U251/NG2 cells, whereas PKCα phosphorylation 
was unchanged (Fig. 3 E). Correspondingly, when NG2 was 
immunoprecipitated from the two sets of cells and immunoblot-
ted with the respective phospho-Thr antibodies, the phosphor-
ylation of NG2 at Thr
2314 was increased in U251/NG2/MEK-DD 
cells relative to that seen in U251/NG2 cells, whereas Thr
2256 
phosphorylation was unaffected.
Differential cell surface localization 
of NG2-T2256E and -T2314E
In U251/NG2 cells, the proteoglycan is present on microprotru-
sions from the apical cell surface (Fig. 4, a–c). It is noteworthy 
that these microprotrusions are infrequently seen on parental 
U251 cells (not depicted) and on NG2-negative cells in the 
U251/NG2 population (Fig. 4, a–c; arrows). In contrast, the mu-
tant NG2-T2256E species that mimics Thr
2256 phosphorylation 
(Makagiansar et al., 2004) is localized to broad lamellipodia 
Figure 2.  In vitro phosphorylation of NG2 fusion proteins by ERK. Two-dimensional analysis reveals two major ERK-phosphorylated peptides derived from 
the wild-type (WT) NG2 cytoplasmic domain and from the T2256E and T2278E mutants. The most highly charged of the two phosphopeptides (spot 1) is 
missing from the T2265E map (arrow), whereas the more neutral phosphopeptide (spot 2) is absent from the T2314E map (arrow). Both phosphopeptides 
are absent from the map of the double mutant (T2265E/T2314E).JCB • VOLUME 178 • NUMBER 1 • 2007  158
(Fig. 4, d–f). As suggested by its coimmunoprecipitation with 
NG2 (Makagiansar et al., 2004), phospho-PKC is also localized 
with NG2-T2256E in lamellipodia (Fig. 4, g–i). Furthermore, in 
both microprotrusions and lamellipodia, NG2 labeling is co-
localized with β1-integrin labeling (Fig. 4, a–f). The α3-integrin 
subunit has an identical localization in these cell types (unpublished 
data), which is consistent with our observation that α3β1 is a pre-
dominant integrin heterodimer in U251 cells (Paulus et al., 1993).
Unlike NG2-T2256E, an NG2-T2314E species designed 
to mimic Thr
2314 phosphorylation is largely present in β1-integrin–
positive arrays of apical microprotrusions reminiscent of those 
seen on U251/NG2 cells. However, in U251/NG2-T2314E 
transfectants, these structures are more highly clustered or bun-
dled than in U251/NG2 cells (Fig. 4, j–l). Cells expressing the 
NG2-T2314V variant resemble parental U251 cells in that they 
rarely display apical protrusions (Fig. 4, m–o). Collectively, 
these data suggest that Thr
2314 phosphorylation not only directs 
NG2 localization to apical microspikes but may actually stimu-
late the formation of these protrusions. We propose that the 
level of Thr
2314 phosphorylation found in U251/NG2 cells under 
basal conditions (Fig. 3) is suffi  cient to induce detectable mi-
crospike formation. Phosphorylation of additional NG2 mole-
cules at Thr
2314, as mimicked by the NG2-T2314E mutant, 
appears to result in aggregation of the microprotrusions. We 
were unable to detect a consistent signal with phospho-ERK 
antibody in any of these cell types and, therefore, were not able 
to determine whether phospho-ERK localizes with NG2 or 
NG2-T2314E in apical microspikes.
Distinct effects of Thr
2314 and Thr
2256 
phosphorylation on cell motility
NG2 expression has been shown to have a stimulatory effect on 
cell motility (Burg et al., 1997; Fang et al., 1999; Grako et al., 
1999). We used transwell migration assays to study the effect of 
PDGF-BB on the motility of U251 cells expressing a variety of 
NG2 species (Fig. 5 A). Under basal conditions (i.e., no PDGF-
BB), no reproducible differences in cell migration are observed 
between parental U251 cells and any of the NG2 transfectants 
except for the NG2-T2256E transfectant, which exhibits strongly 
enhanced migration. This supports our previous fi  nding that   actual 
or mimicked phosphorylation at Thr
2256 promotes cell motil  ity 
(Makagiansar et al., 2004). Notably, glutamic acid substitution at 
Thr
2314 does not have such an effect on basal cell motility.
Although PDGF-BB treatment has a small stimulatory 
effect on the migration of parental U251 cells, the magnitude of 
this stimulation is enhanced in U251/NG2 cells, which migrate 
Figure 3.  ERK-mediated phosphorylation of full-length NG2. (A) NG2 was immunoprecipitated after the treatment of U251/NG2 cells with 20 ng/ml 
PDGF-BB. Immunoblotting of immunoprecipitates with the xTpP and xTpx(K/R) antibodies reveals PDGF-BB–induced increases in NG2 phosphorylation at 
both types of Thr sites. Immunoblotting of total cell extracts for pPKC-α and pERK1/2 as well as for total PKC-α and ERK conﬁ  rm the activation of both kinases 
by PDGF-BB treatment. (B) A375M melanoma cells were stimulated with PDGF-BB and processed as described in A. NG2 immunoprecipitates were immuno-
blotted with the xTpP and xTpx(K/R) antibodies to reveal phosphorylation at both types of motifs. (C) U251/NG2 cells pretreated with either 10 μM 
of the MEK inhibitor U0126 or 100 nM of the PKC-α inhibitor Gö6976 were stimulated with 20 ng/ml PDGF-BB for 20 min. NG2 immunoprecipitates 
were immunoblotted with the two phospho-Thr antibodies. The U0126 reagent blocks NG2 phosphorylation at the xTpP site but not at the xTpx(K/R) site, 
indicating that Thr
2314 is a target for ERK-mediated phosphorylation of full-length NG2, whereas Thr
2265 is not. The additional ability of Gö6976 treatment 
to block phosphorylation at the xTpP site (Thr
2314) suggests that ERK activation is dependent on the action of PKCα. In contrast, U0126 inhibits ERK phos-
phorylation without affecting PKC-α phosphorylation. (D) U251 cells transfected with NG2 variants were analyzed according to the same scheme outlined 
in B. Phosphorylation at Thr
2314 (xTpP blots) is blocked in the NG2-T2314V mutant but occurs normally in both NG2-T2256V and -T2265V. Inhibition by 
U0126 conﬁ  rms these two phosphorylation events as being ERK dependent. Phosphorylation at Thr
2256 (xTpx(K/R) blots) is absent in the NG2-T2256V mu-
tant but occurs normally in both NG2-T2265V and -T23124V. Inhibition of these phosphorylations by Gö6976 demonstrates their dependence on PKC-α. 
(E) Unstimulated U251/NG2 and U251/NG2/MEK-DD cells were analyzed for the phosphorylation of ERK, PKC-α, and NG2. Elevated ERK phosphory-
lation by the activated MEK-DD mutant leads to the increased phosphorylation of NG2 at Thr
2314 but not at Thr
2256.CONSEQUENCES OF NG2 PHOSPHORYLATION BY ERK AND PKCα • MAKAGIANSAR ET AL. 159
at a level comparable with the high basal rate seen with the 
NG2-T2256E transfectants (Fig. 5 A). Thus, although PDGF-
BB treatment is capable of stimulating the motility of U251 
cells via NG2-independent mechanisms, the expression of NG2 
permits an additional increase in PDGF-BB–induced motility 
via PKCα-mediated phosphorylation at Thr
2256. This NG2-
  dependent enhancement of PDGF-BB stimulation is also seen 
in the other mutant transfectants, with the exception of NG2-
T2256V and -T2314E, which respond to PDGF-BB at the same 
modest level as parental U251 cells. For the T2256V transfec-
tant, this loss of responsiveness is explained by the inability of 
PKCα to phosphorylate the mutated site. Regarding the T2314E 
transfectant, it is critical to note that the T2314V mutation does 
not exhibit this same depressed response to PDGF-BB. There-
fore, the inhibitory effect of the T®E substitution is not the 
result of a block of Thr
2314 phosphorylation. Instead, the ability 
of the mutation to mimic ERK-mediated phosphorylation at 
Thr
2314 must counteract, to some degree, the stimulatory effect 
on motility caused by NG2 phosphorylation at Thr
2256.
There are several reports of interactions between NG2 
and β1-integrins, including α4β1 and α3β1 (Iida et al., 1995; 
Doane et al., 1998; Midwood and Salter, 2001; Yang et al., 2004). 
We have documented the ability of exogenous NG2 to activate 
α3β1-integrin signaling on the endothelial cell surface (Fukushi 
et al., 2004). Because membrane-bound NG2 might also be able 
to activate β1-integrin signaling in a cis manner in U251/NG2 
cells, we repeated the cell motility studies in the presence of the 
β1-integrin–blocking antibody P4C10 (Fig. 5 B). This antibody 
substantially inhibits both the PDGF-BB–enhanced motility of 
U251/NG2 cells and the spontaneous motility of NG2-T2256E 
transfectants. An antibody against the α1-integrin subunit, which 
is present at very low levels on these cells, provides a negative 
control for possible nonspecifi  c antibody effects. These results 
suggest that the enhanced motility of U251/NG2 cells in response 
to PDGF-BB is a β1-integrin–dependent process whose activa-
tion is at least partially dependent on the phosphorylation 
of NG2 at Thr
2256.
Distinct effects of Thr
2314 and Thr
2256 
phosphorylation on cell proliferation
Because previous in vitro and in vivo studies have demon-
strated the involvement of NG2 in cell proliferation (Nishiyama 
et al., 1996; Grako et al., 1999; Ozerdem and Stallcup, 2004), 
Figure 4.  Cell surface localization of NG2 species. U251 cells expressing 
NG2 and the mutant species NG2-T2256E, -T2314E, and -T2314V were 
grown overnight under basal conditions. Cells were ﬁ  xed with 4% PFA and 
labeled using a mix of rabbit anti-NG2 antibody (green) and mouse mono-
clonal TS2/16 anti–β1-integrin antibody (red). (a–f) Wild-type NG2 and the 
NG2-T2256E mutant are colocalized with β1-integrin on apical micropro-
trusions (a–c) and leading edge lamellipodia (d–f), respectively. Insets asso-
ciated with a–c represent higher magniﬁ  cations to highlight the colocalization 
of NG2 and β1-integrin in microprotrusions. (g–i) Phospho-PKC is also 
prominent in U251/NG2-T2256E lamellipodia. (j–l) The NG2-T2314E mu-
tant resembles wild-type NG2 in its expression on microprotrusions, although 
these structures are more highly clustered than in U251/NG2 cells. (m–o) 
Microprotrusions are largely absent in U251/NG2-T2314V cells. Arrows in 
a–c and m–o identify cells that have lost NG2 expression. Bar, 10 μm.
Figure 5.  Phosphorylations of NG2 at Thr
2314 and Thr
2256 have opposing 
effects on cell motility. (A) Several U251/NG2 variants were assayed in 
transwell chambers for basal (open bars) and PDGF-BB–induced (closed 
bars) motility. Each bar represents the mean ± SD (error bars) for triplicate 
wells. These results are representative of three separate experiments. NG2 
expression causes enhancement of the basal effect of PDGF-BB seen in pa-
rental U251 cells. The stimulatory effect of NG2 phosphorylation at Thr
2256 
is seen in the enhanced basal motility of the NG2-T2256E variant and in 
the inability of the NG2-T2256V variant to respond to PDGF-BB. An inhibi-
tory effect of Thr
2314 phosphorylation is seen in the reduced PDGF-BB 
  response of the NG2-T2314E variant. *, P < 0.02; **, P < 0.01. (B) Effects 
of integrin-blocking antibodies on the PDGF-BB–induced motility of various 
U251 transfectants. Anti–β1-integrin antibody reduces the increased motil-
ity that results from the actual or mimicked phosphorylation of NG2 at 
Thr
2256. Control anti–α1 antibody has no effect on motility. Each bar repre-
sents the mean ± SD (n = 3). *, P < 0.05; **, P < 0.01.JCB • VOLUME 178 • NUMBER 1 • 2007  160
we investigated the involvement of ERK-mediated NG2 phos-
phorylation in this process. Under basal conditions in the 
absence of exogenous PDGF-BB over the course of 48 h, the 
number of NG2-expressing U251 cells is  50% greater than 
that of parental U251 cells (Fig. 6 A). This is true for both 
conventional U251/NG2 transfectants and U251 cells with 
adenovirally expressed NG2 (Yang et al., 2006). To determine 
whether the increased cell number is caused by increased pro-
liferation or improved survival in the NG2-expressing cells, 
apoptosis levels were assessed via fl  ow cytometry (see Materials 
and methods). The low apoptosis levels we observed (1.2% 
for U251 cells and 2.3% for U251/NG2 cells) cannot explain 
the difference in cell expansion seen in Fig. 6 A, indicating that 
NG2 expression enhances cell proliferation rather than cell sur-
vival under low serum conditions.
Interestingly, the constitutively active MEK-DD con-
struct further enhances the proliferation of U251/NG2 cells 
(Fig. 6 A), suggesting the involvement of the ERK-dependent 
phosphorylation of NG2 at Thr
2314 (Fig. 3 E). To further evalu-
ate this possibility, we studied the effect of PDGF-BB treat-
ment on cell proliferation (Fig. 6 B). PDGF-BB has little effect 
on NG2-negative U251 cells and actually decreases the prolif-
eration of U251/NG2 cells. To determine the respective ef-
fects on proliferation of NG2 phosphorylation at Thr
2256 versus 
Thr
2314, we performed proliferation studies on our panel of 
mutant NG2 transfectants. Under basal conditions, the T2256V 
and T2265V transfectants exhibit enhanced proliferation (rel-
ative to U251 cells) similar to that of the wild-type NG2 trans-
fectant. In contrast, T2314V transfectants have the nonenhanced 
proliferation characteristics of NG2-negative U251 cells. To-
gether with the enhancement produced by MEK-DD, these 
fi  ndings suggest that basal levels of ERK-mediated phosphor-
ylation at Thr
2314 are responsible for NG2-dependent prolifer-
ation under nonstimulatory conditions. After treatment with 
PDGF-BB, decreased cell proliferation is observed for all 
  valine-substituted NG2 transfectants except for the T2256V 
variant, in which PDGF-BB enhances proliferation. This 
behavior may be explained by an inhibitory effect of phos-
phorylation at Thr
2256 by PKCα, which is relieved by the 
NG2-T2256V mutation.
These possibilities were further assessed by examination 
of the T®E substitution variants. By mimicking phosphoryla-
tion at Thr
2256, the NG2-T2256E transfectant reduces both basal 
and PDGF-BB–stimulated cell proliferation to the level of pa-
rental cells, which is in agreement with the hypothesis that the 
Thr
2256 phosphorylation event is inhibitory to cell proliferation. 
In contrast, by mimicking phosphorylation at Thr
2314, the NG2-
T2314E transfectant exhibits increased proliferation beyond 
that seen with any other species, confi  rming the important 
role of Thr
2314 phosphorylation in promoting cell proliferation. 
Treatment of U251/NG2-T2314E cells with PDGF-BB partially 
overcomes this stimulatory effect, most likely as a result of the 
negative effect of Thr
2256 phosphorylation.
In light of the effect of β1-integrin–blocking antibody 
on U251/NG2 cell motility, we repeated the proliferation 
studies in the presence of this same antibody (Fig. 6 C). This 
antibody completely inhibits the increased proliferation seen 
in U251/NG2 cells under basal conditions. The effect of the 
β1 antibody is somewhat less striking in the case of NG2-
T2314E transfectants but is still signifi  cant (P < 0.05) com-
pared with the lack of effect of the control α1 antibody. 
These results indicate that the NG2-dependent increase 
in proliferation seen in U251/NG2 cells is caused by en-
hanced β1-integrin signaling in response to NG2 phosphor-
ylation at Thr
2314.
Figure 6.  The effects of NG2 phosphorylation at Thr
2314 and Thr
2256 are 
reversed in cell proliferation. (A) Cell mass was determined after 48 h for 
serum-starved U251 cells, U251 cells expressing NG2 after adenovirus 
  infection (U251/NG2adv), conventional U251/NG2 transfectants, and 
U251 cells doubly transfected for NG2 and MEK-DD. Both sets of U251/
NG2 cells exhibit higher basal levels of proliferation than parental cells. 
The presence of constitutively active MEK-DD further enhances basal prolif-
eration. Bars represent means ± SD (error bars) in triplicate wells from four 
independent experiments. *, P < 0.005; **, P < 0.001. (B) The protocol 
outlined in A was used to compare the proliferation of wild-type NG2 
transfectants and a variety of NG2 mutants in the absence (open bars) or 
presence (closed bars) of PDGF-BB. PDGF-BB treatment does not affect pro-
liferation of the U251 cells but has a negative effect on that of the NG2 
transfectants. Mimicking Thr
2314 phosphorylation in the NG2-T2314E vari-
ant results in greatly enhanced cell proliferation. Reduction of this elevated 
proliferation by PDGF-BB treatment suggests the possibility of inhibition by 
phosphorylation at Thr
2256. This is supported by the observation that basal 
proliferation of the NG2-T2256E variant is reduced to the level of U251 
parental cells. Moreover, as a result of blocking the Thr
2256 site, prolifera-
tion of the NG2-T2256V variant is enhanced by PDGF-BB treatment rather 
than reduced as seen in every other case. *, P < 0.002; **, P < 0.001. 
(C) Antibody against β1-integrin blocks the stimulatory effect of NG2 
  expression on the basal rate of proliferation in U251/NG2 cells and, to 
some extent, also in NG2-T2314E transfectants. The α1-integrin antibody 
provides a negative control. *, P < 0.05; **, P < 0.0005. (B and C) Each 
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NG2-dependent activation of 𝗃1-integrins
We sought additional evidence for NG2-dependent β1-integrin 
signaling through use of the HUTS-21 monoclonal antibody, 
which binds to the activated form of the β1 subunit (Luque 
et al., 1996; Fukushi et al., 2004). Because we were unable to 
detect HUTS-21 labeling on fi  xed cells, we used living cells for 
these experiments. Although this resulted in the loss of much of 
the morphological detail seen in Fig. 4, several interesting pat-
terns of β1-integrin activation were nevertheless revealed. 
Whereas HUTS-21 binding is detectable only at very low levels 
in U251/NG2 cells (Fig. 7 a), labeling is greatly increased along 
lamellipodial edges in NG2-T2256E transfectants (Fig. 7 c), 
corresponding to the site of NG2 and β1-integrin localization in 
these cells (Fig. 4, d–f). HUTS-21 labeling of NG2-T2314E 
transfectants is also increased (Fig. 7 e) but is more evenly dis-
tributed across the cell surface, which is consistent with the lo-
calization of NG2 and β1-integrin to apical microprotrusions 
(Fig. 4, j–l). In contrast, HUTS-21 binds to the NG2-T2314V 
(Fig. 7 g) and -T2256V (not depicted) transfectants at the basal 
level seen in U251/NG2 cells, supporting the idea that phos-
phorylations at Thr
2314 and Thr
2256 trigger NG2-dependent β1-
integrin activation. As shown by labeling with the β1 antibody 
TS2/16 (Fig. 7, b, d, f, and h), each of the cell types examined 
express comparable levels of total β1-integrin, although integ-
rin distribution is skewed toward lamellipodia in the case of 
U251/NG2-T2256E cells.
Integrin activation is known to trigger the assembly of sig-
naling complexes containing nonreceptor protein tyrosine ki-
nases such as focal adhesion kinase (FAK; for review see Cox 
et al., 2006). Accordingly, we found high levels of tyrosine phos-
phorylation colocalized with NG2 in the lamellipodia of U251/
NG2-T2256E cells (Fig. 8, a–c) and in the microprotrusions of 
U251/NG2-T2314E cells (Fig. 8, d–f). Consistent with the scar-
city of microprotrusions in the absence of NG2 (Fig. 4), this 
type of phosphotyrosine labeling is not seen in cells in the U251/
NG2-T2314E culture that have lost NG2 expression (Fig. 8, d–f; 
arrows). In these cells, phosphotyrosine labeling is faintly visi-
ble in focal adhesion plaques, which are completely obscured by 
the labeling of microprotrusions in NG2-positive cells.
Discussion
Phosphorylation and dephosphorylation have proved to be 
among the most versatile and functionally important types 
of posttranslational modifications (Manning et al., 2002; 
Alonso et al., 2004). In the case of NG2-dependent mecha-
nisms, PKCα-mediated phosphorylation of NG2 at Thr
2256 
triggers increased cell motility via a mechanism that involves 
the translocation of NG2 to sites in leading edge lamelli-
podia of motile cells (Makagiansar et al., 2004). This profound 
effect of phosphorylation on NG2 localization/function 
prompted us to investigate the existence of additional NG2 
Figure 7. Sites  of  𝗃1-integrin activation detected by HUTS-21 and phosphotyrosine antibodies. Living cells were labeled under basal conditions with the 
HUTS-21 antibody (a, c, e, and g) to detect β1-integrin activation and with the TS2/16 antibody (b, d, f, and h) to assess total β1-integrin levels. Compared 
with U251/NG2 cells (a) and U251/NG2-T2314V transfectants (g), U251/NG2-T2256E (c) and U251/NG2-T2314E (e) cells exhibit increased labeling 
with HUTS-21. Cell nuclei were labeled with DAPI. Bar, 10 μm.
Figure 8.  Enhanced phosphotyrosine labeling 
at sites of NG2 expression. After overnight 
growth under basal conditions, PFA-ﬁ  xed U251/
NG2-T2256E (a–c) and U251/NG2-T2314E 
(d–f) cells were used to demonstrate the co-
localization of NG2 (green) and phosphotyro-
sine (red) labeling in lamellipodia (a–c) and 
microprotrusions (d–f). Arrows in d–f indicate 
NG2-negative cells in which phosphotyro-
sine labeling is conﬁ  ned to focal adhesions. 
Bar, 10 μm.JCB • VOLUME 178 • NUMBER 1 • 2007  162
phosphorylation sites capable of influencing other aspects of 
cell biology.
Sequence analysis allows us to identify two previously un-
recognized features of the NG2 cytoplasmic domain: (1) a puta-
tive D domain–docking site for ERK (residues 2,278–2,290) and 
(2) a potential site for ERK-mediated phosphorylation at Thr
2314. 
Immunoprecipitation/immunoblotting results confi  rm the exis-
tence of a physical interaction between NG2 and activated ERK. 
In addition, purifi  ed recombinant ERK is able to phosphorylate 
the isolated NG2 cytoplasmic domain at Thr
2265 and Thr
2314.
In extending these studies to full-length NG2 expressed 
endogenously by A375 melanoma cells or by transfection in 
U251 glioma cells, we used PDGF-BB stimulation to activate 
both PKCα and ERK. This provides a more physiologically rel-
evant means of stimulating phosphorylation than the PMA treat-
ment we previously used to identify PKCα-mediated modifi  cation 
at Thr
2256 (Makagiansar et al., 2004). We evaluated PDGF-
BB–induced phosphorylation of NG2 by immunoblotting with 
phosphospecifi  c antibodies against the xTpx(K/R) motif present 
at Thr
2256 and Thr
2265 and against the xTpP motif present at Thr
2314. 
The use of specifi  c inhibitors of PKCα and ERK coupled with 
analysis of NG2 species with valine substitutions at the putative 
phosphorylation sites reveals that PKCα-mediated phosphoryla-
tion occurs at Thr
2256, whereas ERK-mediated phosphorylation 
occurs only at Thr
2314. Contrary to the results obtained in vitro 
with recombinant ERK treatment of the isolated cytoplasmic 
domain, Thr
2265 is not used as a site for ERK phosphorylation in 
full-length NG2 expressed by living cells. This is more in keeping 
with predictions based on NG2 sequence analysis because the 
residues in the immediate vicinity of Thr
2265 do not represent a 
canonical ERK phosphorylation motif.
An important mechanistic observation from the experi-
ments with NG2-transfected U251 cells is that ERK activation 
in response to PDGF-BB is highly dependent on the activity 
of PKCα. This seems somewhat surprising because conven-
tional wisdom would suggest that PDGF receptors should also 
be able to activate ERK via a Son of sevenless–Ras–Raf–MEK-
dependent pathway (for review see Porter and Vaillancourt, 1998). 
However, the ability of the PKCα inhibitor Gö6976 to inhibit 
both the PKCα-catalyzed phosphorylation of Thr
2256 and the 
ERK-catalyzed phosphorylation of Thr
2314 does not provide evi-
dence for an important contribution of the growth factor–
 activated Son of sevenless–Ras pathway to ERK activation in U251 
cells. A similar dependence of ERK on PKC activity has been 
observed in PDGF stimulation of smooth muscle cells (Robin 
et al., 2004; Ginnan and Singer, 2005). The consequences of these 
fi  ndings in U251 cells are twofold: (1) PDGF-BB treatment in-
evitably activates both PKCα and ERK, thus leading to NG2 
phosphorylation at both Thr
2256 and Thr
2314, and (2) we cannot 
inhibit PKCα without also affecting ERK activity. In this regard, 
the constitutively active MEK-DD construct has provided an ef-
fective means for activating ERK independent of PKCα activa-
tion, enabling us to restrict NG2 phosphorylation to Thr
2314.
Having established the existence of two distinct types of 
Thr phosphorylation sites in the NG2 cytoplasmic domain, we 
addressed the effects of these two phosphorylation events on 
cell behavior. Use of the transwell cell motility assay allows us 
to confi  rm our previous report (Makagiansar et al., 2004) that 
both the actual and mimicked phosphorylation of NG2 at Thr
2256 
leads to enhanced cell migration. Not surprisingly, PDGF-BB 
increases the motility of parental U251 cells via mechanisms 
that are independent of NG2. Nevertheless, the presence of NG2 
further enhances the response to PDGF-BB. The fact that this is 
caused by NG2 phosphorylation at Thr
2256 is demonstrated by 
the loss of enhanced PDGF-BB responsiveness in NG2-T2256V 
transfectants and by the increased motility of NG2-T2256E 
variants even in the absence of growth factor. Notably, the other 
NG2 transfectant that fails to exhibit enhanced NG2-dependent 
motility in response to PDGF-BB is the NG2-T2314E variant. 
Because the NG2-T2314V variant does not exhibit this loss of 
function, the depressed motility of NG2-T2314E transfectants 
cannot be caused by the blockage of Thr
2314 phosphorylation. 
Instead, the defect must be the result of mimicked phosphor-
ylation at this site, indicating that phosphorylation at Thr
2314 
counteracts the stimulation of motility produced by the phos-
phorylation of Thr
2256.
We were also able to identify effects of NG2 phosphoryla-
tion on cell proliferation. In the absence of growth factor stimu-
lation, U251 cells expressing NG2 exhibit a greater rate of cell 
proliferation than parental U251 cells. This phenomenon is 
  observed in both conventionally transfected and adenovirally 
transformed cells, demonstrating that the behavior is indepen-
dent of the means of NG2 expression. Elevated basal rates of 
proliferation are also observed in each of the valine-substituted 
NG2 variants with the exception of NG2-T2314V, suggesting 
that basal levels of phosphorylation at Thr
2314 in nonstimulated 
cells (Fig. 3 A) may be responsible for the increased prolifera-
tion of NG2-expressing U251 cells relative to parental cells. 
Support for this idea is provided by the behavior of U251/NG2/
MEK-DD transfectants and NG2-T2314E transfectants, both of 
which proliferate faster under basal conditions than any other 
species examined because of phosphorylation and mimicked 
phosphorylation at Thr
2314, respectively.
Interestingly, although the addition of PDGF-BB has no 
effect on the proliferation of parental U251 cells, it negatively 
affects the proliferation of U251/NG2 transfectants. This nega-
tive effect of PDGF is also seen in the valine-substituted NG2 
variants with the exception of NG2-T2256V, in which prolifera-
tion is enhanced. The possibility that PDGF-induced phosphor-
ylation at Thr
2256 is capable of reversing the stimulatory effect 
on proliferation caused by Thr
2314 phosphorylation is supported 
by the low rates of proliferation observed in NG2-T2256E 
transfectants, which mimic Thr
2256 phosphorylation.
Our fi  ndings suggest the existence of an intriguing bal-
ance between cell proliferation and migration that can be regu-
lated, in part, by phosphorylation of the NG2 cytoplasmic domain 
at two different sites. PKCα-mediated phosphorylation at 
Thr
2256 appears to stimulate cell motility while inhibiting cell 
proliferation. Conversely, ERK-mediated phosphorylation at 
Thr
2314 tends to block cell motility while promoting cell prolif-
eration. In unstimulated cells, it appears that low levels of Thr
2314 
phosphorylation are responsible for the increased rate of prolif-
eration of U251/NG2 cells compared with parental U251 cells. 
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occurs at both Thr
2314 and Thr
2256. Under these conditions, 
our data suggest that signals generated via Thr
2256 phosphor-
ylation may be dominant over those resulting from Thr
2314 
phosphorylation.
In this context, and considering that both PDGF-induced 
phosphorylation events seem to depend on PKCα activation, it 
is logical to ask under what circumstances Thr
2314 phosphoryla-
tion would lead to increased cell proliferation. An answer may 
lie in the ability of non–growth factor–driven mechanisms to 
activate ERK independently of PKCα activation. An artifi  cial 
example of such a mechanism is provided by our use of the 
MEK-DD construct to drive ERK activation independently of 
PKCα. Under these circumstances, Thr
2314 phosphorylation is 
achieved in the absence of Thr
2256 phosphorylation, resulting in 
the enhancement of cell proliferation. A more biologically rele-
vant means of achieving Thr
2314 phosphorylation independent of 
Thr
2256 phosphorylation might involve the activation of ERK via 
a G protein–coupled receptor-dependent pathway (Pierce et al., 
2001). Alternatively, integrin-mediated activation of the FAK–
src–p130cas pathway could serve to stimulate ERK indepen-
dently of PKCα (Defi  llippi et al., 2006).
With respect to integrins, it is noteworthy that we and oth-
ers have reported the ability of NG2 to activate β1-integrin sig-
naling (Iida et al., 1995; Fukushi et al., 2004; Yang et al., 2004). 
NG2 is able to form a signaling complex with α3β1-integrin 
when the proteoglycan is present in soluble exogenous form or 
when it is expressed in cis fashion on the same cells as the inte-
grin (Fukushi et al., 2004). The relationship between NG2 and 
β1-integrins may be especially relevant to the behavior of 
U251/NG2 cells. Labeling with the activation-dependent 
HUTS-21 antibody reveals β1-integrin activation in U251 cells 
that express the NG2-T2256E and NG2-T2314E variants that 
mimic phosphorylation at Thr
2256 and Thr
2314, respectively. In 
addition, a β1-blocking antibody has inhibitory effects on both 
the proliferation and motility induced by NG2 phosphorylation 
at Thr
2314 and Thr
2256, respectively.
These results are initially paradoxical because it is not im-
mediately clear how integrin activation by NG2 might be able to 
stimulate proliferation in one case (response to Thr
2314 phos-
phorylation) and motility in the other (response to Thr
2256 phos-
phorylation). We suggest two possible resolutions to this 
paradox. First, the two phosphorylated NG2 species might dif-
ferentially infl  uence integrin signaling by interacting with differ-
ent β1-integrin heterodimers or by recruiting additional distinct 
cytoplasmic binding partners to the NG2–β1-integrin complex. 
Second, differential localization of the NG2–integrin complexes 
may be determined by the NG2 phosphorylation pattern with the 
result that integrin signaling occurs in distinctly different micro-
domains of the cell. We have presented evidence consistent with 
this second alternative. Specifi  cally, the NG2-T2256E species is 
localized along with β1-integrin in broad lamellipodia so that 
integrin activation and the resulting tyrosine phosphorylation of 
downstream signaling intermediates are localized to a micro-
domain that is critical to cell motility. In contrast, the NG2-T2314E 
species is colocalized with β1-integrin and elevated tyrosine 
phosphorylation on apical microprotrusions that appear to be 
dependent on NG2 phosphorylation at Thr
2314 for their formation. 
These observations are consistent with the concept that integrin-
mediated signal transduction can activate both motility and pro-
liferation via intermediates such as FAK and Crk-associated 
substrate, whose specifi  c localization patterns determine the out-
come of signaling (for review see Cox et al., 2006).
These proliferation and motility results obtained with 
NG2-transfected U251 cells contradict, to some extent, our pre-
vious results with aortic smooth muscle cells from wild-type 
and NG2-null mice (Grako et al., 1999). Wild-type smooth 
muscle cells proliferated and migrated in response to both 
PDGF-AA and -BB. NG2-null cells failed to respond well to 
PDGF-AA but had normal responses to PDGF-BB. Thus, un-
like our results with U251 glioma cells, the presence or absence 
of NG2 did not affect smooth muscle cell responses to PDGF-BB. 
It seems likely to us that these apparent discrepancies   refl  ect 
the primitive status of our understanding of differences in the 
details of signaling mechanisms that occur from one cell type to 
another. Several examples will serve to illustrate the complexity 
of the situation. (1) We have no information about the phos-
phorylation of NG2 in smooth muscle cells. If PKCα and ERK 
are not activated by PDGF-BB in these cells in the same way we 
have seen in U251 and A375 cells, the phosphorylation of NG2 
at Thr
2256 and Thr
2314 will not occur, and NG2 will have no infl  u-
ence on motility or proliferation. (2) As a result of the proposed 
link between integrin signaling and PDGF receptor activation 
(Borges et al., 2000), the NG2-dependent integrin activation de-
scribed in this study could have an effect on PDGF receptor sig-
naling. Because we have not determined how the spectrum of 
integrins in smooth muscle cells compares with that of U251 
cells, we cannot say whether integrin–PDGF receptor or NG2–
integrin interactions would be comparable between the two cell 
types. (3) PDGF-BB activates signaling through both α and 
β receptors. We have presented evidence for an interaction be-
tween NG2 and PDGFα receptor that potentiates signaling via 
this receptor (Nishiyama et al., 1996; Grako et al., 1999). 
The relative abundance of α and β receptors has been found 
to differ between smooth muscle and glioma cells (Sachinidis 
et al., 1990; Lokker et al., 2002), and we have not determined 
the α/β ratio in the specifi  c cases of our two cell types. There-
fore, we cannot predict the extent to which NG2 itself affects 
PDGF receptor signaling in either cell type. These uncertainties 
make it clear that our understanding of the functional role of 
NG2 is at an early stage and that much additional work will be 
required to elucidate details of the mechanisms by which NG2–
integrin–PDGF receptor interactions regulate cell proliferation 
and motility.
Materials and methods
Reagents
Gö6976 and U0126 were purchased from Calbiochem. PDGF-BB was 
purchased from Chemicon International, and type I collagen was obtained 
from Cohesion.
Antibodies
Afﬁ  nity-puriﬁ  ed rabbit antibody against rat NG2 has been described previ-
ously (Makagiansar et al., 2004). The 9.2.27 monoclonal anti-NG2 anti-
body was a gift from R. Reisfeld (The Scripps Research Institute, La Jolla, 
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xTpx(K/R) and xTpP were purchased from Cell Signaling Technology, as 
were polyclonal anti-ERK1/2 antibody and phosphospeciﬁ  c ERK1/2 and 
PKCα antibodies. Rabbit antibody against phosphotyrosine was provided 
by E. Pasquale (Burnham Institute for Medical Research, La Jolla, CA). 
Monoclonal antibody against PKCα and monoclonal HUTS-21 antibody 
against activated β1-integrin subunit were obtained from BD Biosciences. 
Monoclonal antibodies against human β1-, α3-, and α1-integrin subunits 
were purchased from Chemicon. Fluorescein and rhodamine-coupled sec-
ond antibodies were obtained from Biosource International.
Cell culture and stable transfections
NG2-negative U251MG human astrocytoma cells were maintained in 
DME containing 10% FCS, 2 mM glutamine, 100 IU/ml penicillin, and 
100 μg/ml streptomycin sulfate. U251 cells transfected with cDNA for rat 
NG2 (U251/NG2) have been described previously (Makagiansar et al., 
2004). NG2-positive A375 human melanoma cells and the B5 (anti-NG2) 
hybridoma were obtained from American Type Culture Collection. An ade-
noviral vector containing rat NG2 cDNA (provided by A. Nishiyama, 
University of Connecticut, Storrs, CT) was also used to express NG2 in 
U251 cells (Yang et al., 2006). For this purpose, viral stocks of 10
8 plaque-
forming units/ml were added to semiconﬂ  uent U251 cultures.
Stable transfection with cDNA coding for mutant NG2 species was 
performed as described previously (Stallcup and Dahlin-Huppe, 2001; 
Makagiansar et al., 2004). Mutant NG2 cDNA species were made using 
the QuikChange mutagenesis kit (Stratagene). For some experiments, 
U251/NG2 cells were further transfected with a pUSE vector containing 
the constitutively active MEK-DD mutant (Saxena et al., 1999).
Cell lysis, immunoprecipitation, and Western blotting
Immunoprecipitation and immunoblotting were performed as previously 
described (Makagiansar et al., 2004). In the case of human NG2 from 
A375 cells, immunoprecipitation and immunoblotting were performed with 
the 9.2.27 and B5 monoclonal antibodies, respectively.
Immunoﬂ  uorescence
Cells in culture were ﬁ  xed and labeled as previously described (Stallcup 
and Dahlin-Huppe, 2001; Makagiansar et al., 2004). In the case of HUTS-
21 labeling, living cells were stained at 37°C for 15 min with both ﬁ  rst and 
second antibodies. For phospho-PKC, phospho-ERK, and phosphotyrosine 
labeling, 0.1% Triton X-100 was included in the incubation mix. In double-
labeling studies, controls were included to rule out the cross-reactivity of 
second antibodies with inappropriate Ig species. Specimens were exam-
ined at room temperature using a microscope (Optiphot; Nikon) equipped 
for epiﬂ  uorescence. Images were captured on color slide ﬁ  lm (Fujichrome 
400 ASA; Fuji) using a plan Apo 40× 1.0 NA oil immersion objective 
(Nikon) and scanned at 300 dots per inch resolution using a scanner 
(UY-S77; Sony). Images were saved as Photoshop tif ﬁ  les (3,072 × 2,048 
pixels) and subsequently processed in Photoshop 5.0 (Adobe).
In vitro phosphorylation of NG2 cytoplasmic domain
GST fusion proteins containing the wild-type or mutant NG2 cytoplasmic 
  domain were prepared as described previously (Makagiansar et al., 2004). 
10 μg of fusion protein bound to glutathione–Sepharose beads were used for 
phosphorylation reactions. Protein-laden beads were suspended in 30 μl of 
kinase buffer (50 mM MES, pH 6.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 
100 μM ATP, 10 μCi γ-[P
32]ATP; PerkinElmer) and incubated with 100 ng of 
recombinant ERK2 (Calbiochem) for 30 min at 30°C. In vitro phosphoryla-
tion catalyzed by recombinant PKCα was performed as described previously 
(Makagiansar et al., 2004). Samples were fractionated on 4–20% SDS-
PAGE gels and transferred to Immobilon P. Labeled components were de-
tected by autoradiography. In some cases, in vitro phosphorylation reactions 
were performed using unlabeled ATP. In these cases, phosphorylated bands 
were recognized by immunoblotting with speciﬁ  c phospho-Thr antibodies.
Phosphopeptide mapping
After SDS-PAGE fractionation, 
32P-radiolabeled fusion proteins were cut 
from dried gels and digested with TPCK trypsin (Cooper et al., 1983; 
Makagiansar et al., 2004). Phosphopeptide mapping was performed in 
two dimensions on cellulose TLC plates (Makagiansar et al., 2004).
Cell proliferation assay
After overnight incubation in DME containing 0.5% FCS, cells were har-
vested using enzyme-free cell dissociation buffer and seeded in 0.5% FCS 
medium in 96-well plates (7 × 10
3 cells/well) in the presence or absence 
of 20 ng/ml PDGF-BB. After a 48-h growth period at 37°C, the viable cell 
mass was determined by the addition of MTS (3-[4,5-dimethylthiazol-2yl]-
5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H tetrazolium) phenozine 
methosulfate solution (Promega) to each well. Incubation was continued for 
2 h at 37°C in the dark. Absorbance (490 nm) was then measured on a 
microplate reader (model 550; Bio-Rad Laboratories).
Apoptosis assay
5 × 10
5 cells were seeded in six-well plates and maintained in DME/0.5 
FCS% for 2 d. Both adherent and ﬂ  oating cells were collected and stained 
with annexin V and propidium iodide using the annexin V–FITC apoptosis 
detection kit (Invitrogen). 10
4 cells of each type were analyzed using a 
ﬂ  ow cytometer (FACSort; Becton Dickinson). Parental U251 and U251/
NG2 cell populations were found to contain 1.2% and 2.3% apoptotic 
cells, respectively.
Cell migration assay
Cell migration was examined in transwell cell culture chambers (Costar). 
Polycarbonate membrane inserts (6.5-mm diameter and 8-μM pores) were 
coated overnight by immersion in 30 μg/ml of type I collagen at 4°C. Cells 
grown overnight in DME containing 0.5% FCS were harvested using 
  enzyme-free cell dissociation buffer and were resuspended in medium 
  containing 0.5% FCS. Cells were added to the upper chamber of each well 
(5 × 10
4 cells/well) and incubated at 37°C for 16 h. Where indicated, 
medium in the lower chamber of the well contained 20 ng/ml PDGF-BB. After 
incubation, cells on the upper side of the membrane were removed with a 
cotton swab. The membrane was ﬁ  xed, stained with DAPI, and coverslipped 
with Vectashield (Vector Laboratories). DAPI-positive nuclei were then counted 
under 200× magniﬁ  cation in four contiguous ﬁ  elds of the membrane, ex-
cluding the edges.
Statistical analyses
Statistical analyses were performed using the two-tailed t test.
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